Figures obtained under an FOI request show the NHS spent a whopping £250million in the past five years on treatment for trans ...

New study highlights the potential benefits of breast ultrasound as a supplemental screening tool for women with dense breast ...

Award-winning research presented at ESR 2025 reveals energy-efficient diagnostic approaches for metastatic breast cancer, ...

Health updates cover U.S. involvement in WHO meetings, UK approval of Moderna's RSV vaccine, a Texas measles outbreak, FDA ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the ...

Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

Stephanie Seban received a misdiagnosis of her own stage 4 breast cancer more than a decade ago, but after taking her health into her own hands, she has been able to find treatment to extend her life ...

(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

Philecia La'Bounty uses social media to encourage others to get screenings, be open about their experiences and share her own battles — and her followers have shown appreciation. Read more about her ...

Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast ...

AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...